I think we both have to agree that the timeline is a strong economic disincentive.
Michael Burgess: “I think we both have to agree that the timeline is a strong economic disincentive.”
Editor's note · Context
Burgess highlights FDA approval timelines as a barrier to innovation.
Share
More from Michael Burgess
I am pleased to yield 4 minutes to the gentleman from Missouri (Mr. Alford) for his comments.
I will simply underscore the fact that entry- level chemists at the EPA are hired at much higher than the GSA rate. These are not highly sought-after scientists. These are entry-level applicants, and there is no shortage of applicants for…
I led a letter to the FDA asking them to reclassify naloxone to where you could get it without a prescription.
For the purpose of debate only, I yield the customary 30 minutes to the gentleman from Massachusetts (Mr. McGovern), pending which I yield myself such time as I may consume. During consideration of this resolution, all time yielded is for…





